Regulatory & Legal

The AI security firm regained reporting compliance, but a critical hearing and debt talks will decide its fate as it battles to stay on the exchange.

A new industry group aims to build trust in state-linked stablecoins by setting standards for disclosure and redemption, but is it self-regulation or a prelude to law?

Austrian firm AOP Health secures nationwide access for its rapid heart rate drug, Rapiblyk™, by partnering with top US distributors. What does this mean for critical care?

Unrivaled's renewed partnership with Mount Sinai isn't just a deal; it's a statement on player health, setting a new benchmark for women's pro sports.

Orrstown Financial Advisors is opening a dedicated 4,000 sq. ft. office, signaling a strategic push to enhance client service in a growing regional market.

Inogen reports modest growth and a pivotal return to positive EBITDA, yet a revenue miss from delayed B2B orders raises questions for its turnaround.

With a new board member and strategic investment, Kandu, Inc. is set to scale its brain-computer interface technology for stroke recovery.

A new study reveals payment failures cost billions as customer patience runs out in minutes, creating a crisis for retail and hospitality brands.

After a strategic pivot reverses a year of decline, Allurion's preliminary results show new growth. All eyes are now on the FDA for its 'procedureless' gastric balloon.

Erasca reports promising early data for its pan-RAS inhibitor, ERAS-0015, showing tumor shrinkage at low doses and shaking up the competitive landscape.

Leasing begins at The Orchard, a new luxury giant in Long Island City. But as it sets records, it also raises questions about the neighborhood's future.

The genomics leader posted a 41% revenue surge in 2025 and projects profitability, yet its stock tumbled on what some see as conservative 2026 guidance.

Interim data suggests LX2020 is well-tolerated and may reduce dangerous arrhythmias by targeting the root cause of PKP2-associated cardiomyopathy.

A new White House executive order and a proposed $1.5T budget are shaking up defense contracting. Here's how agile firms like Volatus are set to win.

TriSalus Life Sciences reports record 53% annual revenue growth, but a closer look reveals a complex financial picture for the oncology innovator.

A new clinical trial for AB001, a potent alpha radioligand therapy, offers hope for patients with advanced prostate cancer, including those resistant to current treatments.

As FuelCell Energy eyes larger global projects, it hires a legal expert known for scaling power giants, signaling a strategic shift to execution.

With FDA alignment for its rapid postpartum depression therapy and new trials for anxiety, Reunion Neuroscience is pioneering a new era of mental health.

With key partners secured, Delfin Midstream is set to greenlight America's pioneering floating LNG project, reshaping the global energy map.

With pivotal cancer drug data looming and a new nuclear supply chain, Bicycle Therapeutics is betting big on its novel platform. Will 2026 be its breakout year?